Annovis Bio, Inc. Common Stock (ANVS)

Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company, announced the pricing of an underwritten public offering of 19 million common shares, pre-funded warrants to purchase up to 2 million shares and accompanying warrants to purchase up to 21 million shares. The combined offering price is $1 per common share and accompanying warrant, or $0.9999 per pre-funded warrant and accompanying warrant. The accompanying warrants have an exercise price of $1 per share and expire five years after issuance. Annovis expects gross proceeds of approximately $21 million, excluding potential proceeds from warrant exercises and before deducting offering expenses. The offering is expected to close on or about Nov. 6, 2026, subject to customary closing conditions.

Annovis Bio (NYSE: ANVS) a Phase 3 clinical-stage biotechnology company, announced a proposed underwritten public offering of common stock or pre-funded warrants in lieu of common stock, together with accompanying warrants to purchase common stock. The securities will be issued separately but must be purchased together. Canaccord Genuity is acting as sole bookrunner. Annovis intends to use the net proceeds to advance clinical development of its investigational oral therapy buntanetap for Alzheimer’s disease and Parkinson’s disease, as well as for working capital and general corporate purposes. The proposed offering remains subject to market and other conditions, with no assurance regarding its completion, size or terms.

MALVERN, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the pricing of an underwritten public offering of (i) 19,000,000 shares of its common stock and, in lieu of common stock to certain investors that so chose, pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 2,000,000 shares of its common stock, and (ii) accompanying warrants to purchase up to 21,000,000 shares of common stock. The combined offering price of each share of common stock and accompanying warrant is $1.00, and the combined offering price of each Pre-Funded Warrant to purchase one share of common stock and accompanying warrant is $0.9999, which equals the combined offering price per share of common stock and accompanying warrant, less the $0.0001 per share exercise price of each Pre-Funded Warrant. Each accompanying warrant will be exercisable for one share of common stock at an exercise price of $1.00 per share of common stock, will be exercisable immediately upon issuance and will expire five years after the date of issuance. The Pre-Funded Warrants will be exercisable immediately upon issuance and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full.

MALVERN, Pa., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced that on October 29, 2026, it received notice (the “Notice”) from the New York Stock Exchange (NYSE) that it is no longer in compliance with the NYSE continued listing standards set forth in Section 802.01B of the NYSE’s Listed Company Manual due to the fact that the Company’s average market capitalization over a consecutive 30 trading-day period was less than $50 million while its stockholders’ equity was less than $50 million.

Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy buntanetap for Alzheimer’s and Parkinson’s diseases, announced that Founder, President and CEO Maria Maccecchini, Ph.D., will participate in two industry conferences in November. At U.S. Biotech Day 2026, scheduled for Nov. 16-17 in Philadelphia, Maccecchini will join a panel discussion titled “Bridging the Translational Gap: From Discovery Insights to Clinical Proof” on Nov. 16 from 9:15-9:45 a.m. ET, followed by a company presentation from 10:15-10:30 a.m. ET highlighting Annovis’ clinical programs and upcoming milestones.

Maria Maccecchini, PhD, CEO of Annovis, will join industry panel with pharma leaders and present company updates

Annovis Bio (NYSE: ANVS) announced plans to deliver three presentations at the 19th Clinical Trials on Alzheimer’s Disease (“CTAD”) conference, scheduled for Nov. 16-19, 2026, in Boston. The presentations will highlight the company’s investigational oral therapy buntanetap, including its mechanism of action targeting neurotoxic proteins, the design and baseline characteristics of its pivotal Phase 3 study in early Alzheimer’s disease and the use of artificial intelligence to predict blood-brain barrier permeability of late-stage Alzheimer’s drug candidates.

MALVERN, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced it will attend and present at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) conference, happening November 16-19 in Boston, MA.

Annovis Bio (NYSE: ANVS) announced a collaboration with Weave Bio to support preparation of the planned New Drug Application (“NDA”) for buntanetap, its investigational oral therapy for neurodegenerative diseases including Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”). Annovis will use the Weave AI platform to draft, review and manage NDA documents, while its regulatory and clinical teams will retain responsibility for content, verification and final approval of all documents submitted to the U.S. Food and Drug Administration (“FDA”).

MALVERN, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced a collaboration with Weave Bio, an AI platform for regulatory content and knowledge management, in support of the planned New Drug Application (NDA) for buntanetap.

Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy buntanetap for neurodegenerative diseases including Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), announced it will host a corporate update webinar Sept. 2, 2026, at 4 p.m. EDT, followed by a live question-and-answer session. Founder, President and CEO Maria Maccecchini, Ph.D., will discuss recent progress, ongoing clinical programs and upcoming milestones, including the fully enrolled pivotal Phase 3 AD trial, with top-line data and regulatory submissions expected in 2027. Annovis also plans to begin enrolling patients in an AD open-label study in October 2026 to generate long-term safety data, while its PD open-label study is underway and discussions continue regarding initiation of a Parkinson’s disease dementia program.

MALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced it will host a corporate update webinar followed by a live Q&A session.

MALVERN, Pa., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided business updates and reported financial results for the second quarter ended June 30, 2026.

Pivotal Phase 3 trial enrolls 850 patients, exceeding original projections

Annovis Bio (NYSE: ANVS) announced the promotion of Cheng Fang, Ph.D., to chief scientific officer. Fang, who joined the company in 2021 and most recently served as senior vice president of research and development, will oversee scientific strategy and research operations across Annovis’ Alzheimer’s disease and Parkinson’s disease programs, including translational science, clinical development, biomarker strategy and regulatory interactions.

MALVERN, Pa., July 01, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced the promotion of Cheng Fang, Ph.D., to Chief Scientific Officer.

Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company developing buntanetap for Alzheimer’s disease and Parkinson’s disease, announced it has regained compliance with New York Stock Exchange continued listing standards after implementing corrective measures to restore its market capitalization and stockholders’ equity above required thresholds, allowing its common stock to continue trading on the NYSE under the ticker symbol ANVS.

MALVERN, Pa., May 26, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), announced today that it has regained compliance with the New York Stock Exchange (NYSE) continued listing standards.

Annovis Bio (NYSE: ANVS) announced the pricing of an underwritten public offering of 7,895,000 shares of common stock and accompanying warrants to purchase up to 7,105,500 additional shares at a combined offering price of $1.90 per share and warrant. The company expects gross proceeds of approximately $15 million before expenses, with net proceeds intended to support continued clinical development of buntanetap for Alzheimer’s and Parkinson’s disease, as well as working capital and general corporate purposes.

Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company developing buntanetap for neurodegenerative diseases, announced a proposed underwritten public offering of common stock and accompanying warrants. The company intends to use net proceeds to support continued clinical development of buntanetap in a Phase 3 Alzheimer’s disease study, as well as for working capital and general corporate purposes.

MALVERN, Pa., May 20, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the pricing of an underwritten public offering of 7,895,000 shares of its common stock and accompanying warrants to purchase up to 7,105,500 shares of common stock. The combined offering price of each share of common stock and accompanying warrant is $1.90. Each warrant will be exercisable for one share of common stock at an exercise price of $2.25 per share of common stock, will be exercisable immediately following the issue date and will expire six years after the date of issuance.

MALVERN, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced a proposed underwritten public offering in which it intends to offer and sell (i) shares of its common stock and (ii) accompanying warrants to purchase shares of common stock. The shares of common stock and the accompanying warrants will be issued separately but can only be purchased together in the proposed offering. All of the shares of common stock and the accompanying warrants will be offered by Annovis. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Annovis Bio (NYSE: ANVS) reported first-quarter 2026 business and financial results, highlighting continued advancement of its clinical-stage neurodegenerative disease programs, including 85% enrollment in its pivotal Phase 3 Alzheimer’s disease trial and closure of enrollment to new participants after reaching sufficient screening levels to meet enrollment goals.

MALVERN, Pa., May 15, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided business updates and reported financial results for the first quarter ended March 31, 2026.

Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company developing buntanetap for neurodegenerative diseases including Alzheimer’s disease and Parkinson’s disease, announced that President and CEO Maria Maccecchini, Ph.D., will present at Fierce Biotech Week 2026 in Boston on May 13, discussing the scientific basis for treating Alzheimer’s disease as a multi-protein disorder and highlighting Annovis’ approach of targeting multiple neurotoxic proteins simultaneously through its lead drug candidate, buntanetap, which is currently in a pivotal Phase 3 clinical trial.